論文 - 仲瀬　裕志

Diagnosis and treatment of obscure GI bleeding with double balloon endoscopy.

Hiroshi Nakase, Minoru Matsuura, Sakae Mikami, Tsutomu Chiba

Gastrointestinal endoscopy ( MOSBY-ELSEVIER )  66 ( 3 Suppl ) S78-81 - S81  2007年09月  [査読有り]  [国際誌]

DOI PubMed

Ileal polyposis caused by follicular lymphoma.

Minoru Matsuura, Hiroshi Nakase, Naomi Mochizuki

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association   5 ( 8 ) e30  2007年08月  [査読有り]  [国際誌]

DOI PubMed

Gastrointestinal: Ileal ulcers induced by non-steroidal anti-inflammatory drugs

M. Matsuura, H. Nakase, F. Nakamura, Y. Ueda, S. Mikami, T. Yoshino, S. Ueno, N. Uza, T. Chiba

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY ( BLACKWELL PUBLISHING )  22 ( 8 ) 1346 - 1346  2007年08月  [査読有り]

DOI PubMed

Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease.

Satoko Inoue, Hiroshi Nakase, Minoru Matsuura, Satoru Ueno, Norimitsu Uza, Hiroshi Kitamura, Sakae Mikami, Hiroyuki Tamaki, Katsuhiro Kasahara, Tsutomu Chiba

Journal of gastroenterology and hepatology ( BLACKWELL PUBLISHING )  22 ( 7 ) 984 - 8  2007年07月  [査読有り]  [国際誌]

　概要を見る

BACKGROUND AND AIM: The pathogenesis of Crohn's disease is unclear, but many studies suggest that luminal bacteria play an important role in chronic intestinal inflammation in patients with this condition. Clarithromycin is a macrolide antibiotic with immunomodulatory activity. The aim of this study was to evaluate the effect of clarithromycin therapy in Japanese patients with Crohn's disease. METHODS: Fourteen patients with active Crohn's disease (12 with ileocolonic, one with colonic, one with small bowel type) were treated with oral clarithromycin 200 mg twice daily for 4 weeks. Patients who showed a clinical response within 4 weeks continued the therapy for up to 24 weeks. Four patients also received azathioprine. Clinical activity was assessed with the Crohn's Disease Activity Index (CDAI) at entry and at 4, 12, and 24 weeks after starting clarithromycin. RESULTS: The mean CDAI score at entry was 343.5. Within 4 weeks, eight (57.1%) of the 14 patients showed clinical improvement, and five (35.7%) of the eight patients achieved remission. All of those eight patients continued clarithromycin therapy after 4 weeks, and six (42.9%) were in clinical remission at 12 weeks. Of the 14 total patients, four (28.6%) continued clarithromycin for more than 24 weeks, and have remained in remission. Patients who received azathioprine concomitantly had a better response to clarithromycin therapy. No severe side-effects were observed during the study period. CONCLUSIONS: This open label study showed encouraging results of clarithromycin therapy in Japanese patients with active Crohn's disease.

DOI PubMed

Involvement of cytomegalovirus infection in the ileal lesions of the patient with Behçet's disease.

Sakae Mikami, Hiroshi Nakase, Satoru Ueno, Minoru Matsuura, Takaki Sakurai, Tsutomu Chiba

Inflammatory bowel diseases ( JOHN WILEY & SONS INC )  13 ( 6 ) 802 - 3  2007年06月  [査読有り]  [国際誌]

DOI PubMed

Gastrointestinal: Pneumatosis of the ascending colon

S. Mikami, H. Nakase, T. Sakurai, T. Chiba, S. Shimizu

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY ( BLACKWELL PUBLISHING )  22 ( 5 ) 760 - 760  2007年05月  [査読有り]

DOI PubMed

Localized cytomegalovirus reactivation after radiotherapy for high-grade gastric lymphoma.

Kazuyuki Saga, Toshiro Fukui, Yoko Kato, Toshiki Komeda, Hiroshi Nakase, Norihiko Watanabe, Akiyoshi Nishio, Tsutomu Chiba

Gastrointestinal endoscopy ( MOSBY-ELSEVIER )  65 ( 3 ) 545 - 7  2007年03月  [査読有り]  [国際誌]

DOI PubMed

Hepatobiliary and pancreatic: Hemosuccus pancreaticus

J. Maruyama, H. Nakase, T. Chiba

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY ( BLACKWELL PUBLISHING )  22 ( 3 ) 446 - 446  2007年03月  [査読有り]

DOI

Importance of early detection of cytomegalovirus infection in refractory inflammatory bowel disease.

Hiroshi Nakase, Takuya Yoshino, Satoru Ueno, Norimitsu Uza, Sakae Mikami, Minoru Matsuura, Tsutomu Chiba

Inflammatory bowel diseases ( JOHN WILEY & SONS INC )  13 ( 3 ) 364 - 364  2007年03月  [査読有り]  [国際誌]

DOI PubMed

尿中γ-カルボキシグルタミン酸(Gla)の意義に関する研究 炎症性腸疾患(IBD)患者における骨量低下との関係

桑原 晶子, 辻 秀美, 幣 憲一郎, 仲瀬 裕志, 千葉 勉, 岡野 登志夫, 姫野 雅子, 田中 清, 木戸 詔子

日本病態栄養学会誌 ( (一社)日本病態栄養学会 )  10 ( 1 ) 37 - 44  2007年03月

　概要を見る

炎症性腸疾患(IBD)患者の尿中γ-カルボキシグルタミン酸(Gla)、骨量、血液および尿中の既知の骨吸収マーカーを測定することにより骨減少の実態を明らかにし、尿中Glaの骨代謝マーカーおよびビタミンK栄養状態の指標としての有用性について検討した。炎症性腸疾患患者のうち、ビタミンK製剤と骨吸収抑制剤服用者を除く76例を対象とした。栄養の指標として血清総タンパク、アルブミン、総コレステロール、貧血の指標として赤血球数とヘモグロビン、炎症の指標としてC反応性タンパクと白血球数の測定値を用いた。IBD患者では.尿中Gla高値を示す者がクローン病患者で38%、潰瘍性大腸炎患者で21%存在し、尿中DPDと弱い正の相関が見られた。また、尿中Glaは血清ビタミンKレベルとも正の相関が得られた。

A case of ileal heterotopic pancreas with repeated melena.

Yoko Endo, Shujiro Yazumi, Yuto Kimura, Norimitsu Uza, Minoru Matsuura, Yuzo Kodama, Hiroshi Nakase, Tsutomu Chiba

Gastrointestinal endoscopy ( MOSBY-ELSEVIER )  65 ( 1 ) 156 - 7  2007年01月  [査読有り]  [国際誌]

DOI PubMed

A case of hemorrhagic vascular ectasia of the small intestine, diagnosed and treated by a combination of capsule endoscopy and double balloon endoscopy

K. Okita, S. Miyamoto, T. Kusaka, H. Nakase, M. Matsuura, K. Mizuta, A. Nishio, T. Chiba

Gastroenterological Endoscopy   49 ( 2 ) 190 - 194  2007年  [査読有り]

DOI CiNii J-GLOBAL

Rescue therapy with tacrolimus for a patient with severe ulcerative colitis refractory to combination leukocytapheresis and high-dose corticosteroid therapy.

Hiroshi Nakase, Sakae Mikami, Minoru Matsuura, Satoru Ueno, Norimitsu Uza, Satoko Inoue, Hiroshi Kitamura, Katsuhiro Kasahara, Takuya Yoshino, Yasuhiro Takeda, Tsutomu Chiba

Internal medicine (Tokyo, Japan) ( JAPAN SOC INTERNAL MEDICINE )  46 ( 11 ) 717 - 20  2007年  [査読有り]  [国内誌]

　概要を見る

A19-year-old man complaining of severe diarrhea and hematochezia was admitted to our hospital. Endoscopic findings and laboratory data revealed that he had ulcerative colitis (UC). Despite combination therapy with high-dose corticosteroids and intensive granulocytapheresis, his condition did not improve. Therefore, we initiated tacrolimus therapy. Intravenous administration of tacrolimus with a trough level of 10 to 15 ng/ml relieved his abdominal symptoms within 1 week. The patient experienced no UC relapse 1 year after treatment with oral tacrolimus. Tacrolimus is a promising therapy for patients with UC refractory to the combination of high-dose corticosteroids and leukocytapheresis.

DOI PubMed CiNii

Magnified endoscopic view of primary follicular lymphoma at the duodenal papilla.

Hiroshi Nakase, Minoru Matsuura, Sakae Mikami, Tsutomu Chiba

Internal medicine (Tokyo, Japan) ( JAPAN SOC INTERNAL MEDICINE )  46 ( 3 ) 141 - 2  2007年  [査読有り]  [国内誌]

DOI PubMed CiNii

Hepatobiliary and pancreatic: Hemosuccus pancreaticus

J. Maruyama, H. Nakase, T. Chiba

Journal of Gastroenterology and Hepatology (Australia) ( Blackwell Publishing )  22 ( 3 ) 446  2007年  [査読有り]

DOI PubMed

自己免疫性膵炎患者における抗膵分泌性トリプシンインヒビター自己抗体の同定

浅田 全範, 西尾 彰功, 内田 一茂, 木戸 政博, 上野 哲, 宇座 徳光, 桐谷 景一, 井上 聡子, 北村 浩, 大橋 真也, 玉置 敬之, 福井 寿朗, 松浦 稔, 川崎 公男, 西 俊希, 渡部 則彦, 仲瀬 裕志, 千葉 勉, 岡崎 和一

膵臓 ( Japan Pancreas Society )  22 ( 1 ) 82 - 84  2007年

CiNii

Caecal cancer associated with longstanding Crohn's disease.

Norimitsu Uza, Hiroshi Nakase, Yasuhide Kuwabara, Shigehiko Fujii, Tsutomu Chiba

Lancet (London, England) ( LANCET LTD )  368 ( 9549 ) 1842 - 1842  2006年11月  [査読有り]  [国際誌]

DOI PubMed

炎症性腸疾患(IBD)患者における脂質摂取制限が患者QOLに及ぼす影響

辻 秀美, 幣 憲一郎, 桑原 晶子, 近藤 歌奈, 吉田 朋美, 姫野 雅子, 小川 蓉子, 仲瀬 裕志, 木戸 詔子, 田中 清, 稲垣 暢也

日本病態栄養学会誌 ( (一社)日本病態栄養学会 )  9 ( 4 ) 444 - 444  2006年11月

炎症性腸疾患(IBD)患者の骨量改善への影響因子の検討 尿中Glaと血中脂溶性ビタミンについて

桑原 晶子, 幣 憲一郎, 小川 蓉子, 姫野 雅子, 辻 秀美, 仲瀬 裕志, 千葉 勉, 田中 清, 岡野 登志夫, 木戸 詔子

日本病態栄養学会誌 ( (一社)日本病態栄養学会 )  9 ( 4 ) 531 - 531  2006年11月

Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production.

Hiroyuki Tamaki, Hajime Nakamura, Akiyoshi Nishio, Hiroshi Nakase, Satoru Ueno, Norimitsu Uza, Masahiro Kido, Satoko Inoue, Sakae Mikami, Masanori Asada, Keiichi Kiriya, Hiroshi Kitamura, Shinya Ohashi, Toshiro Fukui, Kimio Kawasaki, Minoru Matsuura, Yasuyuki Ishii, Kazuichi Okazaki, Junji Yodoi, Tsutomu Chiba

Gastroenterology ( W B SAUNDERS CO-ELSEVIER INC )  131 ( 4 ) 1110 - 21  2006年10月  [査読有り]  [国際誌]

　概要を見る

BACKGROUND & AIMS: Thioredoxin-1 (TRX) is a small multifunctional protein with antioxidative and redox-regulating functions. In this study, we investigated the significance of TRX in patients with inflammatory bowel disease (IBD) and the ability and mechanism to ameliorate experimental colitis. METHODS: Serum TRX and macrophage migration inhibitory factor (MIF) levels were measured in patients with IBD. The effects of TRX were evaluated in a dextran sulfate sodium (DSS)-induced colitis model by comparing TRX-overexpressing transgenic (TRX-TG) and control mice. We further evaluated the effect of recombinant human TRX (rhTRX) administration on DSS-induced colitis and colonic inflammation of interleukin (IL)-10 knockout (IL-10 KO) mice. Colonic inflammation was examined clinically and histologically. Proinflammatory cytokine levels were examined in colonic tissues, and MIF levels were measured in colonic tissues and sera in mice. The effect of TRX on MIF production was also analyzed in vitro. RESULTS: Serum TRX and MIF levels were significantly higher in patients with IBD than normal controls, and TRX levels correlated with disease activity. TRX significantly ameliorated DSS-induced colitis and colonic inflammation of IL-10 KO mice. Increase of tumor necrosis factor-alpha and interferon-gamma in colonic tissues was significantly suppressed in TRX-TG mice compared with wild-type mice. MIF levels in colonic tissues and sera were significantly lower in TRX-TG mice than in wild-type mice, irrespective of DSS administration. Anti-TRX treatment exacerbated DSS-induced colitis. In vitro studies demonstrated that rhTRX suppressed MIF production in human monocyte cells. CONCLUSIONS: TRX might have a potential as a novel therapeutic agent for the treatment of IBD.

DOI PubMed